2026-04-13T05:51:36Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1879532025-12-05T12:20:16Zcom_2072_1057col_2072_478916col_2072_478917

00925njm 22002777a 4500 dc Nedkova Hristova, Velina author Baliellas, Carmen author González Costello, José author Lladó, Laura author González Vilatarsana, Emma author Vélez Santamaría, Valentina author Casasnovas Pons, Carlos author 2022-07-22T15:44:37Z 2022-07-22T15:44:37Z 2022-04-13 2022-07-21T09:35:58Z Objectives: To analyze the efficacy and tolerability of diflunisal for the treatment of acquired amyloid neuropathy in domino liver transplant recipients.Methods: We performed a retrospective longitudinal study of prospectively collected data for all domino liver transplant recipients with acquired amyloid neuropathy who received diflunisal at our hospital. Neurological deterioration was defined as an score increase of >= 2 points from baseline on the Neurological Impairment Scale/Neurological Impairment Scale-Lower Limbs.Results: Twelve patients who had received compassionate use treatment with diflunisal were identified, of whom seven had follow-up data for >= 12 months. Five patients (71.4%) presented with neurological deterioration on the Neurological Impairment Scale after 12 months (p = 0.0382). The main adverse effects were cardiovascular and renal, leading to diflunisal being stopped in five patients and the dose being reduced in two patients.Conclusion: Our study suggests that most domino liver transplant recipients with acquired amyloid neuropathy will develop neurological deterioration by 12 months of treatment with diflunisal. This therapy was also associated with a high incidence of adverse effects and low treatment retention. The low efficacy and low tolerability of diflunisal treatment encourage the search for new therapeutic options. Malalties del sistema nerviós Hepatic transplantation Trasplantament hepàtic Nervous system Diseases Treatment With Diflunisal in Domino Liver Transplant Recipients With Acquired Amyloid Neuropathy